Replimune Group (REPL) announced the appointment of Christopher Sarchi as Replimune’s Chief Commercial Officer and the appointment of Sushil Patel, Ph.D., previously Replimune’s Chief Commercial Officer, to a newly created position of Chief Strategy Officer, effective immediately. Chris joins Replimune having recently served as Head of Commercial U.S. Oncology at Sanofi (SNY) where he was responsible for several launches, including the launch of Libtayo as a new standard of care treatment for CSCC.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on REPL:
- Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Replimune to Present at the 41st Annual J.P. Morgan Healthcare Conference
- Barclays views GSK acquisition interest as positive for oncology stocks
- Replimune Group to participate in a conference call with JPMorgan
- Replimune Group price target raised to $58 from $43 at Piper Sandler